Related Experiment Videos
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing
Christopher L Morton1, Peter J Houghton, E Anders Kolb
1St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Pediatric Blood & Cancer
|June 29, 2010
Summary
Seneca Valley virus (NTX-010) shows significant antitumor activity against neuroblastoma and rhabdomyosarcoma in preclinical studies. Further research will identify cancer cell characteristics associated with NTX-010 response.
Area of Science:
- Oncolytic virotherapy
- Cancer research
- Viral oncology
Background:
- Seneca Valley virus (NTX-010) is an RNA virus in Phase 1 clinical trials for neuroendocrine tumors.
- Systemic administration of NTX-010 was evaluated for antitumor activity.
Purpose of the Study:
- To assess the in vitro and in vivo antitumor efficacy of NTX-010.
- To identify cancer types responsive to NTX-010 treatment.
Main Methods:
- In vitro cytotoxicity testing against 23 cell lines.
- In vivo xenograft studies with systemic NTX-010 administration.
- Evaluation of objective response, tumor volume (T/C), and event-free survival (EFS).
Main Results:
- NTX-010 exhibited significant in vitro cytotoxicity in neuroblastoma, Ewing sarcoma, and rhabdomyosarcoma cell lines.
- Consistent in vivo activity was observed in rhabdomyosarcoma and neuroblastoma xenografts, with complete responses (CR) achieved.
- Objective responses were also noted in rhabdoid tumor, Wilms tumor, and glioblastoma models.
Conclusions:
- NTX-010 demonstrated potent antitumor activity both in vitro and in vivo.
- Further studies are needed to define molecular characteristics of cancer cells that predict response to NTX-010.
